Zkusit zdarma
MeiraGTx Holdings plc

MeiraGTx Holdings plc

MGTX
Cena:
$ 9.24
-0.25 (-2.63%)
Valuace
100
Růst
100
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

4:30 15-05-2026

MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcrip...

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

16:30 14-05-2026

LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertic...

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates

10:10 14-05-2026

MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.57 per share versus the Zacks Cons...

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

8:00 14-05-2026

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from ...

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know

11:00 05-05-2026

MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnin...

MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?

MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?

7:55 20-04-2026

MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The la...

MeiraGTx (NASDAQ:MGTX) Sees Strong Trading Volume on Analyst Upgrade

MeiraGTx (NASDAQ:MGTX) Sees Strong Trading Volume on Analyst Upgrade

1:01 18-04-2026

MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) shares saw unusually-strong trading volume on...

MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript

MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity Transcript

17:01 16-04-2026

MeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerost...

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

10:16 16-04-2026

XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral...

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

7:47 16-04-2026

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a ve...

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

7:10 16-04-2026

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a ve...

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

7:00 16-04-2026

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a ve...

MeiraGTx: Turning Dry Mouth Into Liquid Gold

MeiraGTx: Turning Dry Mouth Into Liquid Gold

13:26 15-04-2026

MeiraGTx is approaching a pivotal Phase 1 data readout for AAV-hAQP1 in radiation-induced xerostomia...

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

8:30 14-04-2026

- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-...

Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?

Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?

10:21 31-03-2026

MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than avera...

MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript

MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript

16:45 27-03-2026

MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transc...

Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock

Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock

4:22 27-03-2026

MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) CEO Alexandria Forbes sold 62,000 shares of t...

MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates

MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates

10:16 26-03-2026

MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $0.19 per share, beating the Zacks ...

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

8:00 26-03-2026

FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3...

MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

4:28 16-03-2026

Shares of MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) have received an average rating of ...

close

ZIPBIO AND MEIRAGTX ENTER INTO EXCLUSIVE LICENSE AGREEMENT TO ADVANCE FIRST-IN-CLASS AAV GENE THERAPY FOR GEOGRAPHIC ATROPHY

03-02-2026
BOSTON, FEB. 3, 2026 /PRNEWSWIRE/ -- ZIPBIO, A BIOTECHNOLOGY COMPANY PIONEERING AI-DRIVEN PROTEIN T...
Více zde

GRAVITON BIOSCIENCE TO PRESENT SELECTIVE ROCK2 OBESITY DATA AT 8TH ANNUAL EVERCORE HEALTHCONX CONFERENCE

20-11-2025
NEW YORK , NOV. 20, 2025 /PRNEWSWIRE/ -- GRAVITON BIOSCIENCE CORPORATION, A CLINICAL-STAGE BIOTECHN...
Více zde

MEIRAGTX REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATIONAL RESULTS

13-11-2025
LONDON AND NEW YORK, NOV. 13, 2025 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A VER...
Více zde

MEIRAGTX ENTERS INTO STRATEGIC COLLABORATION WITH ELI LILLY AND COMPANY TO DEVELOP AND COMMERCIALIZE GENETIC MEDICINES IN OPHTHALMOLOGY

10-11-2025
LONDON AND NEW YORK, NOV. 10, 2025 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A VER...
Více zde

MEIRAGTX ANNOUNCES TWO POSTERS AT THE EUROPEAN SOCIETY OF GENE AND CELL THERAPY (ESGCT) 2025 ANNUAL CONGRESS

07-10-2025
LONDON AND NEW YORK, OCT. 07, 2025 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A VER...
Více zde

MEIRAGTX REPORTS SECOND QUARTER 2025 FINANCIAL AND OPERATIONAL RESULTS

14-08-2025
-  GAINED ALIGNMENT WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) ON THE ONGOING PHASE 2 AQUAX2 RAN...
Více zde

MEIRAGTX ANNOUNCES THE PRESENTATION OF FOUR POSTERS AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) 2025 ANNUAL MEETING

13-05-2025
MULTIPLE POSTER PRESENTATIONS HIGHLIGHT THE DEPTH AND NOVELTY OF MEIRAGTX'S TECHNOLOGY PLATFORMS FOR...
Více zde

MEIRAGTX REPORTS FIRST QUARTER 2025 FINANCIAL AND OPERATIONAL RESULTS

13-05-2025
-  ANNOUNCED STRATEGIC COLLABORATION WITH HOLOGEN AI, INCLUDING A $200 MILLION CASH UPFRONT PAYMENT...
Více zde

MEIRAGTX GRANTED FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR AAV-GAD FOR THE TREATMENT OF PARKINSON'S DISEASE

09-05-2025
-  THIS RMAT DESIGNATION IS BASED ON DATA FROM 3 CLINICAL STUDIES DEMONSTRATING THE POTENTIAL BENEF...
Více zde

CONE ROD DYSTROPHY MARKET REPORT 2025-2030, WITH PROFILES OF SPARINGVISION, BEACON THERAPEUTICS, NANOSCOPE THERAPEUTICS, MEIRAGTX, ASCIDIAN THERAPEUTICS, JCYTE, BLUEROCK THERAPEUTICS AND MORE

29-04-2025
THE GLOBAL CONE ROD DYSTROPHY MARKET, VALUED AT US$131.29 MILLION IN 2024, IS PROJECTED TO REACH US$...
Více zde

MEIRAGTX REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL AND OPERATIONAL RESULTS AND RECENT BUSINESS UPDATES

13-03-2025
-  TODAY ANNOUNCED STRATEGIC COLLABORATION WITH HOLOGEN AI, INCLUDING A $200 MILLION UPFRONT PAYMEN...
Více zde

MEIRAGTX ENTERS INTO A STRATEGIC COLLABORATION WITH HOLOGEN AI TO EXPEDITE PHASE 3 DEVELOPMENT OF AAV-GAD FOR PARKINSON'S DISEASE AND INDUSTRIALIZE MEIRAGTX'S PROPRIETARY MANUFACTURING PROCESS

13-03-2025
- MEIRAGTX TO RECEIVE $200 MILLION IN UPFRONT CASH CONSIDERATION - MEIRAGTX AND HOLOGEN WILL FORM A ...
Více zde

MEIRAGTX ANNOUNCES THE LANCET PUBLICATION OF DATA DEMONSTRATING THE EFFICACY OF RAAV8.HRKP.AIPL1 FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS 4 (LCA4) RETINAL DYSTROPHY

21-02-2025
LONDON AND NEW YORK, FEB. 21, 2025 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A VE...
Více zde

MEIRAGTX RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR AAV8-RK-RETGC FOR THE TREATMENT OF PATIENTS WITH LEBER CONGENITAL AMAUROSIS DUE TO GUCY2D MUTATIONS

22-01-2025
MEIRAGTX HAS RECENTLY RECEIVED RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FOR FOUR INHERITED RETINAL ...
Více zde

MEIRAGTX ANNOUNCES POSTER PRESENTATION ON A POTENTIAL TREATMENT FOR MC4R GENETIC DEFICIENCY AT THE 2024 SOCIETY FOR NEUROSCIENCE CONFERENCE

09-10-2024
RESULTS INDICATE A POTENT AND EFFECTIVE LOCALLY DELIVERED AAV-BDNF GENE THERAPY FOR THE TREATMENT OF...
Více zde

MEIRAGTX ANNOUNCES $50 MILLION OFFERING OF ORDINARY SHARES LED BY SANOFI AND REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS

12-08-2024
- POSITIVE DATA FROM THE PHASE 1 AQUAX STUDY IN RADIATION-INDUCED XEROSTOMIA (RIX) PRESENTED AT THE...
Více zde

MEIRAGTX ANNOUNCES PRICING OF OFFERING OF ORDINARY SHARES LED BY SANOFI

12-08-2024
LONDON AND NEW YORK, AUG. 12, 2024 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A VE...
Více zde

MEIRAGTX REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS

09-05-2024
- POSITIVE DATA FROM THE PHASE 1 AQUAX STUDY IN RADIATION-INDUCED XEROSTOMIA (RIX) PRESENTED IN AN O...
Více zde

MEIRAGTX TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

24-04-2024
LONDON AND NEW YORK, APRIL 24, 2024 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A VE...
Více zde

MEIRAGTX ANNOUNCES ORAL PRESENTATION AT THE 2024 AMERICAN ACADEMY OF ORAL MEDICINE (AAOM) ANNUAL CONFERENCE

18-04-2024
LONDON AND NEW YORK, APRIL 18, 2024 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A V...
Více zde

MEIRAGTX REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATIONAL RESULTS AND RECENT BUSINESS UPDATES

14-03-2024
- COMPANY ALIGNED WITH FDA ON REQUIREMENTS FOR ONGOING PHASE 2 AQUAX2 CLINICAL TRIAL FOR GRADE 2/3 R...
Více zde

MEIRAGTX ANNOUNCES ASSET PURCHASE AGREEMENT INVOLVING ITS AAV-RPGR COLLABORATION FOR UP TO $415 MILLION

21-12-2023
- MEIRAGTX ENTERS INTO AN ASSET PURCHASE AGREEMENT RELATED TO BOTARETIGENE SPAROPARVOVEC (BOTA-VEC, ...
Více zde

MEIRAGTX TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

21-11-2023
LONDON AND NEW YORK, NOV. 21, 2023 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ:MGTX), A VE...
Více zde

MEIRAGTX ANNOUNCES THIRD QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS

14-11-2023
- RECEIVED STRATEGIC INVESTMENT FROM SANOFI PURCHASING $30 MILLION OF ORDINARY SHARES OF THE COMPANY...
Více zde

MEIRAGTX ANNOUNCES $30 MILLION STRATEGIC INVESTMENT FROM SANOFI; COMPANY PURSUING MULTIPLE ADDITIONAL STRATEGIC OPPORTUNITIES

30-10-2023
LONDON AND NEW YORK, OCT. 30, 2023 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A VE...
Více zde

MEIRAGTX ANNOUNCES AN ORAL PRESENTATION AND EIGHT POSTERS AT THE EUROPEAN SOCIETY OF GENE AND CELL THERAPY (ESGCT) 2023 ANNUAL CONGRESS

24-10-2023
MULTIPLE POSTERS AND ORAL PRESENTATIONS HIGHLIGHT THE DEPTH OF INNOVATION FROM MEIRAGTX'S TECHNOLOGY...
Více zde

MEIRAGTX REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS

10-08-2023
LONDON AND NEW YORK, AUG. 10, 2023 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A VE...
Více zde

MEIRAGTX ANNOUNCES POSTER PRESENTATION AT THE 2023 AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) SPOTLIGHT ON IMMUNO-ONCOLOGY

01-08-2023
RIBOCAR-T CELL ACTIVITY CAN BE PRECISELY TUNED AND “REMOTELY” CONTROLLED TO IMPROVE THE EFFICACY...
Více zde

MEIRAGTX ANNOUNCES ITS WHOLLY-OWNED GENE THERAPY MANUFACTURING FACILITY IN SHANNON, IRELAND HAS RECEIVED COMMERCIAL MIA AUTHORIZATION FOR QC TESTING

19-07-2023
LONDON AND NEW YORK, JULY 19, 2023 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ: MGTX), A VERTI...
Více zde

MEIRAGTX ANNOUNCES POSITIVE CLINICAL DATA FROM THE AQUAX PHASE 1 CLINICAL STUDY OF AAV2-HAQP1 FOR THE TREATMENT OF GRADE 2/3 RADIATION-INDUCED XEROSTOMIA

27-06-2023
LONDON AND NEW YORK, JUNE 27, 2023 (GLOBE NEWSWIRE) -- MEIRAGTX HOLDINGS PLC (NASDAQ:MGTX), A VERT...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-02 00:00:008-KStáhnout
2025-11-13 00:00:008-KStáhnout
2025-11-13 00:00:0010-QStáhnout
2025-11-10 00:00:008-KStáhnout
2025-08-14 01:00:008-KStáhnout
2025-08-14 01:00:0010-QStáhnout
2025-08-14 00:00:008-KStáhnout
2025-08-14 00:00:0010-QStáhnout
2025-06-26 01:00:008-KStáhnout
2025-06-26 00:00:008-KStáhnout
2025-06-17 01:00:008-KStáhnout
2025-06-17 00:00:008-KStáhnout
2025-05-13 01:00:008-KStáhnout
2025-05-13 01:00:0010-QStáhnout
2025-05-13 00:00:008-KStáhnout
2025-05-13 00:00:0010-QStáhnout
2025-05-09 01:00:008-KStáhnout
2025-05-09 00:00:008-KStáhnout
2025-04-04 01:00:008-KStáhnout
2025-04-04 00:00:008-KStáhnout
2025-03-13 00:00:008-KStáhnout
2025-03-13 00:00:0010-KStáhnout
2025-03-12 23:00:008-KStáhnout
2025-03-12 23:00:0010-KStáhnout
2024-12-09 00:00:008-KStáhnout
2024-12-08 23:00:008-KStáhnout
2024-11-13 00:00:008-KStáhnout
2024-11-13 00:00:0010-QStáhnout
2024-11-12 23:00:008-KStáhnout
2024-11-12 23:00:0010-QStáhnout
2024-10-15 01:00:008-KStáhnout
2024-10-15 00:00:008-KStáhnout
2024-08-13 01:00:008-KStáhnout
2024-08-13 00:00:008-KStáhnout
2024-08-12 01:00:008-KStáhnout
2024-08-12 01:00:0010-QStáhnout
2024-08-12 00:00:008-KStáhnout
2024-08-12 00:00:0010-QStáhnout
2024-06-10 01:00:008-KStáhnout
2024-06-10 00:00:008-KStáhnout
2024-05-09 01:00:008-KStáhnout
2024-05-09 01:00:0010-QStáhnout
2024-05-09 00:00:008-KStáhnout
2024-05-09 00:00:0010-QStáhnout
2024-03-15 00:00:0010-KStáhnout
2024-03-14 23:00:0010-KStáhnout
2024-03-14 00:00:008-KStáhnout
2024-03-13 23:00:008-KStáhnout
2024-02-13 00:00:008-KStáhnout
2024-02-12 23:00:008-KStáhnout
2023-12-21 00:00:008-KStáhnout
2023-12-20 23:00:008-KStáhnout
2023-10-30 00:00:008-KStáhnout
2023-10-29 23:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-06-12 01:00:008-KStáhnout
2023-06-12 00:00:008-KStáhnout
2023-05-11 01:00:008-KStáhnout
2023-05-11 01:00:0010-QStáhnout
2023-05-11 00:00:008-KStáhnout
2023-05-11 00:00:0010-QStáhnout
2023-05-09 01:00:008-KStáhnout
2023-05-09 00:00:008-KStáhnout
2023-04-26 01:00:008-KStáhnout
2023-04-26 00:00:008-KStáhnout
2023-03-14 00:00:008-KStáhnout
2023-03-14 00:00:0010-KStáhnout
2023-03-13 23:00:008-KStáhnout
2023-03-13 23:00:0010-KStáhnout
2023-03-10 00:00:008-KStáhnout
2023-03-09 23:00:008-KStáhnout
2022-11-10 00:00:008-KStáhnout
2022-11-10 00:00:0010-QStáhnout
2022-11-09 23:00:008-KStáhnout
2022-11-09 23:00:0010-QStáhnout
2022-08-11 01:00:008-KStáhnout
2022-08-11 01:00:0010-QStáhnout
2022-08-11 00:00:008-KStáhnout
2022-08-11 00:00:0010-QStáhnout
2022-08-04 01:00:008-KStáhnout
2022-08-04 00:00:008-KStáhnout
2022-06-27 01:00:008-KStáhnout
2022-06-27 00:00:008-KStáhnout
2022-06-09 01:00:008-KStáhnout
2022-06-09 00:00:008-KStáhnout
2022-05-12 01:00:008-KStáhnout
2022-05-12 01:00:0010-QStáhnout
2022-05-12 00:00:008-KStáhnout
2022-05-12 00:00:0010-QStáhnout
2022-04-27 01:00:008-KStáhnout
2022-04-27 00:00:008-KStáhnout
2022-03-10 00:00:008-KStáhnout
2022-03-10 00:00:0010-KStáhnout
2022-03-09 23:00:008-KStáhnout
2022-03-09 23:00:0010-KStáhnout
2021-12-07 00:00:008-KStáhnout
2021-12-06 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-08-11 01:00:008-KStáhnout
2021-08-11 01:00:0010-QStáhnout
2021-08-11 00:00:008-KStáhnout
2021-08-11 00:00:0010-QStáhnout
2021-06-11 01:00:008-KStáhnout
2021-06-11 00:00:008-KStáhnout
2021-05-11 01:00:008-KStáhnout
2021-05-11 01:00:0010-QStáhnout
2021-05-11 00:00:008-KStáhnout
2021-05-11 00:00:0010-QStáhnout
2021-03-11 00:00:008-KStáhnout
2021-03-11 00:00:0010-KStáhnout
2021-03-10 23:00:008-KStáhnout
2021-03-10 23:00:0010-KStáhnout
2020-12-17 00:00:008-KStáhnout
2020-12-16 23:00:008-KStáhnout
2020-11-23 00:00:008-KStáhnout
2020-11-22 23:00:008-KStáhnout
2020-11-18 00:00:008-KStáhnout
2020-11-17 23:00:008-KStáhnout
2020-11-16 00:00:008-KStáhnout
2020-11-15 23:00:008-KStáhnout
2020-11-05 00:00:008-KStáhnout
2020-11-05 00:00:0010-QStáhnout
2020-11-04 23:00:008-KStáhnout
2020-11-04 23:00:0010-QStáhnout
2020-10-06 01:00:008-KStáhnout
2020-10-06 00:00:008-KStáhnout
2020-08-06 01:00:008-KStáhnout
2020-08-06 01:00:0010-QStáhnout
2020-08-06 00:00:008-KStáhnout
2020-08-06 00:00:0010-QStáhnout
2020-07-17 01:00:008-KStáhnout
2020-07-17 00:00:008-KStáhnout
2020-06-08 01:00:008-KStáhnout
2020-06-08 00:00:008-KStáhnout
2020-05-07 01:00:008-KStáhnout
2020-05-07 01:00:0010-QStáhnout
2020-05-07 00:00:008-KStáhnout
2020-05-07 00:00:0010-QStáhnout
2020-03-11 00:00:008-KStáhnout
2020-03-11 00:00:0010-KStáhnout
2020-03-10 23:00:008-KStáhnout
2020-03-10 23:00:0010-KStáhnout
2019-11-07 00:00:008-KStáhnout
2019-11-07 00:00:0010-QStáhnout
2019-11-06 23:00:008-KStáhnout
2019-11-06 23:00:0010-QStáhnout
2019-08-09 01:00:008-KStáhnout
2019-08-09 00:00:008-KStáhnout
2019-08-07 01:00:008-KStáhnout
2019-08-07 01:00:0010-QStáhnout
2019-08-07 00:00:008-KStáhnout
2019-08-07 00:00:0010-QStáhnout
2019-06-20 01:00:008-KStáhnout
2019-06-20 00:00:008-KStáhnout
2019-06-04 01:00:008-KStáhnout
2019-06-04 00:00:008-KStáhnout
2019-05-15 01:00:008-KStáhnout
2019-05-15 00:00:008-KStáhnout
2019-05-14 01:00:0010-QStáhnout
2019-05-14 00:00:0010-QStáhnout
2019-05-10 01:00:008-KStáhnout
2019-05-10 00:00:008-KStáhnout
2019-04-22 01:00:008-KStáhnout
2019-04-22 00:00:008-KStáhnout
2019-03-26 00:00:008-KStáhnout
2019-03-26 00:00:0010-KStáhnout
2019-03-25 23:00:008-KStáhnout
2019-03-25 23:00:0010-KStáhnout
2019-03-04 00:00:008-KStáhnout
2019-03-03 23:00:008-KStáhnout
2019-02-27 00:00:008-KStáhnout
2019-02-26 23:00:008-KStáhnout
2019-02-22 00:00:008-KStáhnout
2019-02-21 23:00:008-KStáhnout
2019-02-05 00:00:008-KStáhnout
2019-02-04 23:00:008-KStáhnout
2019-02-04 00:00:008-KStáhnout
2019-02-03 23:00:008-KStáhnout
2018-12-20 00:00:008-KStáhnout
2018-12-19 23:00:008-KStáhnout
2018-11-08 00:00:008-KStáhnout
2018-11-08 00:00:0010-QStáhnout
2018-11-07 23:00:008-KStáhnout
2018-11-07 23:00:0010-QStáhnout
2018-10-09 01:00:008-KStáhnout
2018-10-09 00:00:008-KStáhnout
2018-08-08 01:00:008-KStáhnout
2018-08-08 01:00:0010-QStáhnout
2018-08-08 00:00:008-KStáhnout
2018-08-08 00:00:0010-QStáhnout
preloader